Focus On Chronic Lymphocytic Leu​kemia


​​​DAY 1 | ​Racial & Ethnic Disparities for Patients With Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is typically a slower-progressing hematologic malignancy of the lymphocytes. This disease is frequently diagnosed in older patients, and racially, it is estimated that White people comprise roughly 87-89 percent of the cases in the U.S. annually. Consequently, since there are fewer cases of CLL in people of other races, less is known about this disease in those populations. Early research efforts evaluating CLL in patients of ethnic and racial minorities showed that there was generally lower survival in those populations compared to White patients with that disease.​ Read More >

​​​​​​DAY​ 1 | ​​3-Year Efficacy Data of Phase II CAPTIVATE Study for CLL/SLL

The use of the first-in-class Bruton’s tyrosine kinase inhibitor ibrutinib has revolutionized the treatment of hematologic malignancies. Likewise, the initial BCL-2 inhibitor venetoclax has also been widely explored in the treatment of hematologic malignancies. The combination of ibrutinib and venetoclax was explored in treatment-naïve chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the Phase II CAPTIVATE study. One of the cohorts of this research involved a fixed-duration (FD) dosing of combined ibrutinib/venetoclax.​ Read More >

​​DAY 2 | Evaluating Racial & Socioeconomic Disparities in CLL Patients

A recent study showed that Black race and low socioeconomic status are prognostic of overall survival in patients with chronic lymphocytic leukemia, according to findings presented during the ASCO 2022 Annual Meeting (Abstract 7542). Additional study is required to better understand the reasons behind this issue, according to the researchers. Read More >

​​​​​DAY 3 |​ ​Dose-Escalation Data of LAVA-051 in CLL & Multiple Myeloma

During the 2022 ASCO Annual Meeting, researchers presented initial dose-escalation data from the Phase I/IIa clinical trial of LAVA-051 in patients with chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) (Abstract 2577).​"​ Read More >

​​​​DAY 3 |​ ​5-Year Follow-Up Data From the Phase III ELEVATE-TN Study

At 5-year follow-up, the efficacy and safety of acalabrutinib plus obinutuzumab and acalabrutinib monotherapy were maintained among chronic lymphocytic leukemia (CLL) patients, according to data recently presented at the 2022 ASCO Annual Meeting (Abstract 7539). The data also showed a significantly longer overall survival with acalabrutinib plus obinutuzumab compared with obinutuzumab plus chlorambucil. Read More >

​​​DAY 1 |​ ​Survival Outcomes for CLL Patients in Academic vs. Non-Academic Centers

A recent study of a large population of chronic lymphocytic leukemia patients demonstrated significant demographic and socioeconomic variation between individuals treated at academic centers versus non-academic centers. The researchers also found, according to data presented during the ASCO 2022 Annual Meeting, that patients treated at academic centers had improved survival compared to those treated at all other facility types. Read More >

​​DAY 2 | ​Zilovertamab Plus Ibrutinib Shows Promise in CLL & MCL Patients

Phase I/II findings presented during the 2022 ASCO Annual Meeting demonstrated that zilovertamab plus ibrutinib is well-tolerated among chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) patients (Abstract 7520). Read More ​>

​​​​DAY 2 | Extended Follow-Up Supports Efficacy of Triplet Regimen in CLL Patients

Remissions remain durable among chronic lymphocytic leukemia patients treated with fixed duration obinutuzumab, ibrutinib, and venetoclax, according to 4-year follow-up data presented during the 2022 ASCO Annual Meeting, held in Chicago from June 3-7 (Abstract 7540). Read More ​>

​​​​DAY 3 |​ ​TakeAim Leukemia & TakeAim Lymphoma Studies Discussed at ASCO 2022

Encouraging clinical data from both the TakeAim Leukemia and studies TakeAim Lymphoma were presented at the 2022 ASCO Annual Meeting. The researchers focused on the use of emavusertib in combination with ibrutinib in patients with Non-Hodgkin's Lymphoma, as well as emavusertib's “encouraging monotherapy activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)."​ Read More >

Discover Highlights for the 2022 ASCO Annual Meeting

The 2022 ASCO Annual Meeting, which will be held both in-person and online June 3-7, provides an opportunity to explore the latest advancements in cancer research, treatment, and patient care. This year's theme will be Advancing Equitable Cancer Care Through Innovation, with more than 200 sessions offering resources and research on this topic.​ Read More >